It is incredibly likely the reason that Frequency Therapeutics refused to recognise the positive reports regarding tinnitus improvement is due to it being an unqualified fact from a research/trial perspective.It's been a while since I've posted this, but I think it needs to be near the top again:
Tinnitus Talk Podcast:
Re: Patients that received FX-322 in the Phase 1/2 trial.
"... there is anecdotal reports as patients have come back and visited with ENTs when they have had conversations with them about how they are doing. Some of them have offered that they have had improvements in tinnitus, there's nothing that we can quantitate there. Again, it adds to the excitement of the opportunity. "
- Carl LeBel, Frequency Therapeutics
Pretty sure this is simply a nice way which Frequency Therapeutics can hint that there's the possibility of positive influence on tinnitus with FX-322, without violating their FDA obligation of not making misleading and/or false claims.